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A patient with Bardet–Biedl Syndrome (BBS), on the basis of frequent presence of obstructive
sleep apnea in obese, snoring patients, was evaluated by a polisomnograhic (PSG) study. The
PSG showed severe obstructive sleep apnea (RDI ¼ 45.7; Sat HbO2o90% for 98% of sleep
time). The patient was successfully treated with nasal-continuous positive airway pressure
(n-CPAP), and after three months, a PSG control demonstrated a strong reduction of
respiratory distress index (RDI), normalization of oxyhemoglobin saturation recording and
some other clinical improvements (arterial blood pressure, serum creatinine and protein-
C-reactive). This is the ﬁrst report of OSAS in BBS. We believe that is important to inquire
further into the presence of sleep apnea in this genetic disorder, because the recognition that
some of the clinical ﬁndings could be caused or worsened by OSAS may lead to adequate
therapy and improve the clinical course and quality of life of the affected individuals.
& 2008 Elsevier Ltd. All rights reserved.Introduction
Bardet–Biedl syndrome (BBS) is a genetically heterogeneous
disease mapping to eight known loci (pleiotropic genetic
disorder).1 The clinical cardinal features are obesity, retinalElsevier Ltd. All rights reserved.
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ft.it (M. Polverino).dystrophy, polydactyly, hypogenitalism, renal abnormalities
and learning disabilities. Other clinical ﬁndings (secondary
features) include diabetes, hypertension, congenital heart
defects, strabismus/cataracts/astigmatism, brachydactyly/
syndactyly, dental crowding/hypodontia/small roots/high
arched palate, developmental delay.2
The obesity is also a well-known risk factor for the
development of OSAS, which, in turn, can lead to cardiac
and renal dysfunctions.3
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Table 1 Comparison of PSG parameters at the time of
diagnosis and after three months of nasal-CPAP therapy.
Parameters Diagnosis After three months
RDI 46 11
AI 13 10
DI 78 18
Timeo90% 98% 0.5%
Timeo80% 68% 0%
PLM index 29/h 3/h
First description of obstructive sleep apnea 183Other genetic syndromes associated with obesity present
obstructive sleep apnea syndrome (OSAS) as frequent
clinical features (such as Down syndrome, Beckwith–Wiede-
mann syndrome, Prader–Willi syndrome),4 but, up until now,
there has not been a description of OSAS in BBS.
We report a case of a 13-year-old male affected by BBS
with OSAS successfully treated with nasal-continuous posi-
tive airway pressure (n-CPAP).
Case report
A 13-year-old male affected by BBS presented with the
following clinical features: obesity, retinal dystrophy, renal
anomalies (had a renal transplantation in 1999), hypogonad-
ism and hypospadia, neurosensorial deafness (had a cochlear
implantation in 2003), developmental delay, brachydactyly,
arterial hypertension. The patient presented also a history
of nocturnal snoring, without evidence of adeno-tonsillar
hypertrophy.
Polisomnographic (PSG) study
The patient underwent standard overnight PSG (Compume-
dics S-series; Australia), which included continuous record-
ing of electroencephalography (EEG), electro-oculography
(EOG) and chin electromyography (EMG) for sleep staging
according to the criteria of Rechtshaffen and Kales.5 Nasal
and oral termisthores were used to measure airﬂow and
inductance plethysmography to measure rib cage and
abdominal movements. Leg EMG, electrocardiogram (ECG),
oxyhemoglobin saturation (SaO2), snoring and body position
were also continuously monitored.
PSG results
Total recording time was 404min (total sleep time-
399min; sleep efﬁciency ¼ 98%; sleep latency ¼ 6min).
The hypnogram showed REM sleep ¼ 22.1% (REM sleep
latency ¼ 86min); Stage 1 ¼ 2.9%; Stage 2 ¼ 16.8%; Stage
3 ¼ 21.8%; Stage 4 ¼ 36.5%. Arousal index (no. of arousal/h)
was 20.3.
Respiratory analysis demonstrates 89 obstructive sleep
apneas with an apnea index (no. apneas/h) of 13.4 and 215
hypopneas with a respiratory disturbance index (no. of
apneas and hypopneas/h) of 45.7. The Sat HbO2 was o90%
for 98% and o80% for 68% of sleep time; the lowest
desaturation waso50. Periodic leg movements (PLMs) were
recorded, and the PLM index (no. of PLM/h) was 29 (normal
value o5).
n-CPAP treatment
After a period of adaptation, the patient began a home
therapy with nasal auto-CPAP (Good-Night 420E-Mallin-
crokdt; pressure range: 5–15 cmH2O). After three months,
the patient underwent a PSG control during n-CPAP
ventilation. There was no evidence of changes in sleep
macrostructure, but a strong reduction of RDI and PLM
index, and normalization of oxyhemoglobin saturation
during sleep (Table 1 and Figure 1).The parents reported an improvement in nocturnal
breathing without snoring and increased involvement in
diurnal activities. After six months of n-CPAP therapy there
were some other clinical improvements with respect to the
previous six months, such as lowering of blood pressure,
serum creatinine and protein-C-reactive (PCR) (Table 2).
Analysis of data was done using a spreadsheet program
and a statistical software package (GB-Stat v65). Compar-
ison of variable before and after n-CPAP was made using a
one-tailed paired Student t test. A p value of o0.05 was
considered to be statistically signiﬁcant.Discussion
The patient in this report, affected by BBS, presented many
complex abnormalities, including severe arterial hyperten-
sion, who was under multi-drug therapy (labetalol, furose-
mide, amlodipine and losartan). Cyclosporine and
prednisone were given after the renal transplantation to
avoid reject. The patient also presented a clinical picture of
nocturnal snoring and difﬁcult breathing with diurnal
somnolence. The PSG study demonstrated a severe OSAS,
normal sleep architecture and numerous arousals correlated
with respiratory and PLM events. The arousal’s and PLM
index’s increase are presumably responsible for the poor
quality of sleep even if its macrostructure (hypnogram) was
normal.
The n-CPAP therapy immediately improved PSG ﬁndings
with a reduction of respiratory events, and also improved
desaturation index and the quality of sleep (normalization of
arousals and PLM index). In the six-month follow-up after
starting n-CPAP, a signiﬁcant decrease of arterial hyperten-
sion and serum creatinine was also recorded, together with
a signiﬁcant reduction of the systemic hallmark of inﬂam-
mation (PCR).
It is known that apnea obstructive syndrome is frequently
coupled with many genetic syndromes, especially in the
presence of obesity, which is a feature of at least 24 genetic
disorders.6 So it is not surprising to ﬁnd OSAS in BBS, a
genetic syndrome with obesity.
We do not know which is the cause of apnea syndrome in
this patient affected by BBS, because there were many
possible causes: upper airway involvement by neuromuscu-
lar impairment, obesity, other anatomo-clinical features of
the genetic syndrome.
In any case, the recognition and the treatment of OSAS
have lead, in our patient, to a signiﬁcant improvement of
ARTICLE IN PRESS
Figure 1 Comparison of nocturnal saturimetric pattern at time of diagnosis (upper) and after three months of n-CPAP therapy
(lower).
Table 2 Comparison of some clinical parameters in the previous six months of n-CPAP and in the six months of n-CPAP
therapy (mean value71 standard deviation).
Parameters Six months previous of n-CPAP (n) Six months of n-CPAP (n) p
SBP 118712 (9) 101713 (7) 0.018
DBP 8079 (9) 6877 (7) 0.012
Serum creatinine 0.9170.07 (7) 0.7870.12 (6) 0.029
PCR 19.9711 (5) 572 (5) 0.010
SBP ¼ systolic blood pressure; DBP ¼ diastolic blood pressure; PCR ¼ serum protein-C-reactive.
D. Viggiano et al.184some clinical impairments: for the ﬁrst time blood pressure
was constantly normal in all the recordings (from the mean
value of 118/80 in the three pre-treatment months to
the mean value of 101/68 in the n-CPAP period). We know
that OSAS is a signiﬁcant risk factor of systemic and
pulmonary hypertension,3 which can be signiﬁcantly im-
proved by n-CPAP.
The renal abnormalities and the chronic steroid therapy
for the transplant can also be the cause of arterial
hypertension. In our report, on the basis of the improvement
of arterial hypertension with n-CPAP, we can postulate that,
at least partially, part of the hypertension can be caused by
the coexistent OSAS.
Under the same spotlight we can judge the improvements
of the PCR. At this time we have no evidence to judge
whether the increase of PCR is attributable to the clinical
picture of the genetic syndrome or to the OSAS, but, based
on our case report, we can postulate that part of the clinical
framework of the patient could be attributed to the OSAS
and not to the genetic syndrome
Conclusion
Many genetic and syndromic disorders are frequently
associated with apnea syndromes. This is the ﬁrst report of
OSAS in BBS. We believe that it is important to inquire
further into the presence of sleep apnea in this geneticdisorder, because some of the clinical ﬁndings, mistakenly
attributed to the genetic syndrome, could be caused or
worsened by OSAS and an adequate therapy may improve
the clinical course and quality of life of the affected
patients.
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